NERV - ミネルバ・ニュ―ロサイエンシズ (Minerva Neurosciences Inc) ミネルバ・ニュ―ロサイエンシズ

 NERVのチャート


 NERVの企業情報

symbol NERV
会社名 Minerva Neurosciences Inc (ミネルバ・ニュ―ロサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ミネルバ・ニューロサイエンス(Minerva Neurosciences Inc. )は臨床段階のバイオ医薬品会社である。同社は中枢神経系(CNS)疾患に患う患者を治療するために、製品候補のポートフォリオを開発・商品化する。同社の製品ポートフォリオは統合失調症の治療用MIN-101、不眠症およびうつ病障害(MDD)の治療用MIN-202、MDDの治療用MIN-117及びパーキンソン病の治療用MIN-301を含む。MIN-101は気分、認知、睡眠および不安の調節に関与する脳内の2つの受容体であるセロトニン受容体およびシグマ受容体を遮断する化合物である。MIN-117は5-ヒドロキシトリプタミンタイプ1A(5-HT1A)と呼ばれるセロトニン受容体の特定のサブタイプを遮断する。MIN-202は選択的オレキシン2受容体アンタゴニストである。MIN-301はパーキンソン病の治療のためのニューレグリン-1 1b1(NRG-1b1)タンパク質の可溶性組換え形態である。   ミネルバ・ニュ―ロサイエンシズは、米国のバイオ医薬品会社。中枢神経系(CNS)疾患の患者を治療するため、製品の開発、実用化に注力する。臨床段階にある主要な薬剤候補は、「MIN-101」や「MIN-117」など。統合失調症、大うつ病性障害、不眠症、パ―キンソン病の治療のため、治験薬の開発を行っている。   Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
本社所在地 1601 Trapelo Road Suite 286 Waltham MA 02451 USA
代表者氏名 Remy Luthringer レミー・ライスリンガー
代表者役職名 Executive Chairman of the Board Chief Executive Officer
電話番号 +1 617-600-7373
設立年月日 39173
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 12人
url www.minervaneurosciences.com
nasdaq_url https://www.nasdaq.com/symbol/nerv
adr_tso
EBITDA EBITDA(百万ドル) -46.60467
終値(lastsale) 11.17
時価総額(marketcap) 433109411.31
時価総額 時価総額(百万ドル) 409.84480
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 302.75407
当期純利益 当期純利益(百万ドル) -45.44626
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Minerva Neurosciences Inc revenues was not reported. Net loss increased 22% to $24.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.57 to -$0.64.

 NERVのテクニカル分析


 NERVのニュース

   Minerva Neurosciences, Inc: Minerva Neurosciences to Present at JMP Securities Life Sciences Conference  2021/06/10 12:41:00 FinanzNachrichten
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat
   Minerva Neurosciences to Present at JMP Securities Life Sciences Conference  2021/06/10 12:30:00 Intrado Digital Media
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.
   Minerva Neurosciences, Inc: Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference  2021/05/28 12:05:00 FinanzNachrichten
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat c
   Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference  2021/05/28 00:00:00 BioSpace
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.
   Minerva Neuroscie (NERV) falls 9.69% for May 19  2021/05/19 22:00:25 Equities
Minerva Neuroscie (NASDAQ: NERV) shares fell -9.69% to end trading Wednesday at $3.17 per share - a net change of $-0.34. Shares traded between $3.40 and $3.07 throughout the day. 1531475 shares of Minerva Neuroscie exchanged hands. Visit Minerva Neuroscies profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Minerva Neuroscie and to follow the companys latest updates, you can visit the companys profile page here: Minerva Neuroscies Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   Minerva Neurosciences, Inc: Minerva Neurosciences to Present at JMP Securities Life Sciences Conference  2021/06/10 12:41:00 FinanzNachrichten
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat
   Minerva Neurosciences to Present at JMP Securities Life Sciences Conference  2021/06/10 12:30:00 Intrado Digital Media
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.
   Minerva Neurosciences, Inc: Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference  2021/05/28 12:05:00 FinanzNachrichten
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat c
   Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference  2021/05/28 00:00:00 BioSpace
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.
   Minerva Neuroscie (NERV) falls 9.69% for May 19  2021/05/19 22:00:25 Equities
Minerva Neuroscie (NASDAQ: NERV) shares fell -9.69% to end trading Wednesday at $3.17 per share - a net change of $-0.34. Shares traded between $3.40 and $3.07 throughout the day. 1531475 shares of Minerva Neuroscie exchanged hands. Visit Minerva Neuroscies profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Minerva Neuroscie and to follow the companys latest updates, you can visit the companys profile page here: Minerva Neuroscies Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   Minerva Neurosciences: Q4 Earnings Snapshot  2021/03/08 12:47:39 San Francisco Chronicle
WALTHAM, Mass. (AP) _ Minerva Neurosciences Inc. (NERV) on Monday reported a loss of $7.3…
   Earnings Scheduled For March 8, 2021  2021/03/08 09:05:17 Benzinga
Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is expected to report quarterly earnings at $0.19 per share on revenue of $94.70 million. • Ondas Holdings (NASDAQ: ONDS ) is projected to report earnings for its fourth quarter. • Paya Holdings (NASDAQ: PAYA ) is likely to report quarterly earnings at $0.04 per share on revenue of $53.28 million. • XPeng (NYSE: XPEV ) is likely to report quarterly loss at $0.12 per share on revenue of $412.10 million. • Rand Capital (NASDAQ: RAND ) is estimated to report earnings for its fourth quarter. • Minerva Neurosciences (NASDAQ: NERV ) is likely to report earnings for its fourth quarter. • Nine Energy Service (NYSE: NINE ) is estimated to report quarterly loss at $0.84 per share on revenue of $56.55 million. • RadNet (NASDAQ: RDNT ) is projected to report quarterly earnings at $0.15 per share on revenue of $300.63 million. • Niu Technologies (NASDAQ: NIU ) is likely to report quarterly earnings at $0.09 per share on revenue of $95.31 million. • Addex Therapeutics (NASDAQ: ADXN ) is estimated to report earnings for its fourth quarter.
   DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2021/02/08 16:30:00 Benzinga
LOS ANGELES , Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva" or "the Company") (NASDAQ: NERV ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b -5 promulgated thereunder by the U.S. Securities and Exchange Commission. … Full story available on Benzinga.com
   DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2021/02/07 20:53:49 NewMediaWire
Los Angeles, CA - (NewMediaWire) - February 7, 2021 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. (“Minerva” or “the Company”) (NASDAQ: NERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 15, 2017 and November 30, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before February 8, 2021. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.
   MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2021/02/06 19:32:41 NewMediaWire
Los Angeles, CA - (NewMediaWire) - February 6, 2021 -The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. (“Minerva” or “the Company”) (NASDAQ: NERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 15, 2017 and November 30, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before February 8, 2021. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ミネルバ・ニュ―ロサイエンシズ NERV Minerva Neurosciences Inc)

 twitter  (公式ツイッターやCEOツイッターなど)